238 related articles for article (PubMed ID: 25100280)
21. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
22. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.
Fretellier N; Idée J; Bruneval P; Guerret S; Daubiné F; Jestin G; Factor C; Poveda N; Dencausse A; Massicot F; Laprévote O; Mandet C; Bouzian N; Port M; Corot C
Br J Pharmacol; 2012 Feb; 165(4b):1151-62. PubMed ID: 21740412
[TBL] [Abstract][Full Text] [Related]
23. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella MA; Reilly RF
Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
[TBL] [Abstract][Full Text] [Related]
24. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
25. Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis.
Bose C; Megyesi JK; Shah SV; Hiatt KM; Hall KA; Karaduta O; Swaminathan S
PLoS One; 2015; 10(8):e0136563. PubMed ID: 26305890
[TBL] [Abstract][Full Text] [Related]
26. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.
Ashouri H; Riyahi Alam N; Khoobi M; Haghgoo S; Rasouli Z; Gholami M
Magn Reson Imaging; 2024 Apr; 107():120-129. PubMed ID: 38215955
[TBL] [Abstract][Full Text] [Related]
27. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
28. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
Bernstein EJ; Schmidt-Lauber C; Kay J
Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
[TBL] [Abstract][Full Text] [Related]
29. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.
Wermuth PJ; Del Galdo F; Jiménez SA
Arthritis Rheum; 2009 May; 60(5):1508-18. PubMed ID: 19404939
[TBL] [Abstract][Full Text] [Related]
30. Renal failure and gadolinium. The number of documented cases is rising.
Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
[No Abstract] [Full Text] [Related]
31. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
Gupta A; Shamseddin MK; Khaira A
Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
[TBL] [Abstract][Full Text] [Related]
32. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
Idée JM; Fretellier N; Robic C; Corot C
Crit Rev Toxicol; 2014 Nov; 44(10):895-913. PubMed ID: 25257840
[TBL] [Abstract][Full Text] [Related]
33. Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis.
Drel VR; Tan C; Barnes JL; Gorin Y; Lee DY; Wagner B
FASEB J; 2016 Sep; 30(9):3026-38. PubMed ID: 27221979
[TBL] [Abstract][Full Text] [Related]
34. Effects of Gadodiamide on cell proliferation and collagen production in cultured human dermal fibroblasts.
Ozawa Y; Hayashi S; Hamasaki Y; Hatamochi A
Arch Dermatol Res; 2016 Dec; 308(10):695-701. PubMed ID: 27683230
[TBL] [Abstract][Full Text] [Related]
35. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
[TBL] [Abstract][Full Text] [Related]
36. [The Grenelle of MR contrast agents?].
Clément O
J Radiol; 2007 Nov; 88(11 Pt 1):1663. PubMed ID: 18065924
[No Abstract] [Full Text] [Related]
37. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
[TBL] [Abstract][Full Text] [Related]
38. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
Grant D; Johnsen H; Juelsrud A; Løvhaug D
Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
[TBL] [Abstract][Full Text] [Related]
39. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
Abraham JL; Edward M
AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
[No Abstract] [Full Text] [Related]
40. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
Prasad SR; Jagirdar J
J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
